Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...

Invitae’s business operations are heading to a new home. Under a bankruptcy auction, Labcorp was selected as the winning bidder for the firm’s genetic testing services, digital health solutions, and ...

Overseen by a newly appointed CEO, genetic testing company Invitae will lay off more than 1,000 employees as part of a year-long restructuring plan that’s expected to ultimately save the company ...

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin ...

– Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies – – May provide real-time data on therapy response, support patient ...

Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind to receive FDA marketing authorization. Invitae is ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae rolled up several ...

Invitae, a medical genetic testing company, has filed for Chapter 11 bankruptcy and intends to continue the case without disrupting operations using cash on hand and while seeking to sell its business ...

SAN FRANCISCO-- (BUSINESS WIRE)-- Invitae Corporation (NYSE:NVTA), a genetic information company, and TME Research, LLC today announced the initiation of a new clinical collaboration to evaluate the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min More than 4 million people have ...

Invitae's business has been growing rapidly and there's still more growth on the horizon. The beaten-up stock is a risky buy given its significant losses and persistent cash burn. There's significant ...